Alazocine

Alazocine

Alazocine
Systematic (IUPAC) name
(2R,6R,11R)-6,11-Dimethyl-3-prop-2-en-1-yl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
Clinical data
Legal status
  • Uncontrolled
Routes ?
Identifiers
CAS number  N
ATC code None
PubChem
ChemSpider  YesY
ChEMBL  YesY
Chemical data
Formula C17H23NO 
Mol. mass 257.37 g/mol
 N   

Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM).[1][2][3] It has no significant affinity for the σ2 receptor.[3] Alazocine also acts as a κ-opioid receptor agonist (Ki = 0.4 nM), and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).[3][4]

See also

References

  1. ^ Iwamoto ET (February 1981). "Pharmacologic effects of N-allylnormetazocine (SKF-10047)". NIDA Research Monograph 34: 82–8.  
  2. ^ Shearman GT, Herz A (August 1982). "Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat". European Journal of Pharmacology 82 (3–4): 167–72.  
  3. ^ a b c Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research 821 (2): 516–9.  
  4. ^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology 6 (1): 3.